ODTX — Odyssey Therapeutics, Inc.
ODTX dilution and offerings
- Float: 24.0M shares
🔔 Alert me if ODTX files an offering or S-3
$21.57+10.45%
Last close: · regular session
Last 33 sessions
Float: 24.0M shares. Latest SEC filing: 8-K on Nov 4, 2026. ODTX closed at $21.57 (+10.45%) on Nov 3, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for ODTX in the TickerWise workspace.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 100
- Website: https://odysseytx.com
Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg; a TSLP/IL-33 bispecific antagonist; an oral small molecule interleukin-1 receptorassociated kinase 4 scaffolding inhibitor; and a small molecule inhibitor of IRF5. The company was incorporated in 2021 and is headquartered in Boston, Massachusetts.
Latest SEC filings for ODTX
Latest ODTX news
- Odyssey Therapeutics Announces Oral Presentation of Additional Phase 2a Induction Data for OD-001 in Ulcerative Colitis at UEG Week 2026 Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.